High BCL11A Expression in Adult Acute Myeloid Leukemia Patients Predicts a Worse Clinical Outcome.

BACKGROUND

Recent reports showed BCL11A may be causatively involved in myeloid leukemia. This study investigated the relationship between BCL11A expression levels and adult acute myeloid leukemia patient characteristics as well as clinical outcomes.

METHODS

RT-PCR was employed to detect BCL11A gene expression levels in 80 patients with acute myeloid leukemia.

RESULTS

Median BCL11A expression levels of 80 AML bone marrow samples were found to be higher than the control group (0.039 vs. 0.014, p < 0.005). Patients with low BCL11A expression levels had a significantly higher CR (complete remission) rate compared with patients with high BCL11A expression levels (90% vs. 53%, p < 0.005). Moreover, the median OS (overall survival) in patients with low BCL11A expression (268 d) was also longer than that in patients with high BCL11A expression (101.5 d) (p < 0.05). No significant difference was observed between the high and low BCL11A groups with respect to white blood cells, haemoglobin, platelet count, French-American-Britain (FAB) subtypes, percentage of blasts in bone marrow, peripheral blood, cytogenetic risk groups, and CD34 expression.

CONCLUSIONS

Adult acute myeloid leukemia had a higher BCL11A expression level. High BCL11A expression level was correlated with lower CR rate and shorter OS, suggesting that BCL11A expression could potentially be used as a prognosis indicator.